AGP Executive Report
Last update: 4 hours agoBiotech Deal: New Brunswick-based Johnson & Johnson agreed to buy Ollin Biosciences for $2.2 billion upfront, adding an experimental eye-disease drug that is headed for Phase 3 trials. Alzheimer’s Testing: Quanterix and Sherman Abrams Laboratory will expand access to blood-based Alzheimer’s tests in New Jersey and nearby areas. South Jersey Health Tech: Shore Medical Center and Shore Physicians Group plan to adopt one AI-powered Oracle Health record system across hospital and outpatient care. Fertility Care: CCRM Fertility of New Jersey in Livingston performed the first commercial procedure using Rejoni’s Juveena hydrogel system, designed to help prevent uterine adhesions from returning after surgery. Cancer Treatment: The FDA approved Biocon’s biosimilar to Perjeta, adding a lower-cost treatment option for HER2-positive breast cancer; Biocon is based in Bridgewater. Air Travel Technology: A faulty router triggered last week’s nationwide FAA ground stop, disrupting flights and costing the U.S. economy billions, according to Transportation Secretary Sean Duffy. The outage renewed calls to upgrade aging air traffic systems, including at Newark.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.